Tokyo, Japan, November 11, 2025 \u2013 RealizeEdge Partners Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Yoshitsugu Shitaka, Ph.D.; \u201cRealizeEdge Partners\u201d) today announced the alliance with Axcelead Drug Discovery Partners, Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Representative Director, President & CEO: Kengo Okada, Ph.D.; \u201cAxcelead DDP\u201d), a leading drug discovery solutions provider, and Xeureka Inc. (Head Office: Minato-ku, Tokyo; President & CEO: Taisei Nagae; \u201cXeureka\u201d), a specialist in AI-powered drug discovery.
The collaboration will lead to the launch of a new startup (\u201cTPD\/DAC newCo\u201d) dedicated to developing novel therapeutics based on Targeted Protein Degraders (TPDs) and Degrader-Antibody Conjugates (DACs*)- an emerging modality that combines TPDs with antibodies.<\/p>\n\n\n\n
RealizeEdge Partners supports the commercialization of drug discovery seeds originating from researchers and entrepreneurs. The launch of TPD\/DAC newCo represents the first concrete initiative under this mission. RealizeEdge Partners will continue to collaborate with academia, startups, pharmaceutical companies, venture capital firms, and related organizations to identify promising assets and technologies. * Degrader-Antibody Conjugate (DAC) technology involves conjugating a targeted protein degrader to an antibody. This approach combines the high target selectivity of antibody therapeutics with the potent pharmacological activity of protein degraders, unlocking therapeutic strategies for targets and diseases previously considered intractable with conventional antibody drugs or antibody-drug conjugates (ADCs).<\/p>\n\n\n\n Axcelead DDP is Japan\u2019s first drug discovery solutions provider, established in July 2017 after inheriting the drug discovery platform from Takeda Pharmaceutical Company Limited. We provide comprehensive drug discovery services through a fully integrated research platform that consolidates all essential functions and infrastructure\u2014including a large-scale compound library, screening, chemistry, pharmacology\/biology, DMPK and safety\u2014under one roof. Furthermore, by combining our extensive experience and expertise with a proprietary AI platform, we can rapidly generate high-quality novel drug candidate compounds. This integrated setup enables us to deliver efficient and flexible one-stop solutions through a seamless framework, tailored to meet diverse needs in drug discovery from target identification to bridging into clinical development. Xeureka is an AI-powered drug discovery company established in November 2021 as a wholly owned subsidiary of Mitsui and Co., Ltd. Leveraging cutting-edge technologies such as advanced AI and simulations, the company aims to significantly improve efficiency and success rates in drug discovery research. Utilizing its proprietary supercomputer and computational drug discovery technologies, Xeureka provides AI-driven drug discovery services and conducts collaborative research and development with pharmaceutical companies. Additionally, the company leads the Tokyo-1 Project, an innovation hub for the healthcare industry with a focus on drug discovery. RealizeEdge Partners is a Tokyo-based startup studio established in April 2025. We support innovators with breakthrough ideas to accelerate the creation of drug discovery startups transforming health and brightening lives by integrating scientific excellence with strategic and operational support. <\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":"Tokyo, Japan, November 11, 2025 \u2013 RealizeEdge Partners Co., Ltd. (Head Office: Chuo-ku, Tokyo; President […]","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,2],"tags":[],"class_list":["post-31","post","type-post","status-publish","format-standard","hentry","category-press_release","category-news"],"_links":{"self":[{"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/posts\/31","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/comments?post=31"}],"version-history":[{"count":4,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/posts\/31\/revisions"}],"predecessor-version":[{"id":42,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/posts\/31\/revisions\/42"}],"wp:attachment":[{"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/media?parent=31"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/categories?post=31"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/realizeedge.com\/en\/wp-json\/wp\/v2\/tags?post=31"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Through this collaboration, the three companies will integrate their respective expertise across AI-driven molecular design and optimization, compound synthesis, screening, and in vitro<\/em> evaluation.
The aim is to accelerate lead program development and fundraising, enabling seamless support from early research to business implementation.<\/p>\n\n\n\n\u25a0 Future Outlook<\/strong><\/h4>\n\n\n\n
By designing tailored collaboration models for each project, the company aims to advance the social implementation of innovative drug discovery seeds and contribute to the creation of new therapeutic solutions.<\/p>\n\n\n\nAbout Axcelead DDP<\/strong><\/h4>\n\n\n\n
For more information, please visit https:\/\/axcelead-us.com\/<\/a><\/p>\n\n\n\nAbout Xeureka<\/strong><\/h4>\n\n\n\n
Website: https:\/\/xeureka.co.jp\/en\/<\/a><\/p>\n\n\n\nAbout RealizeEdge Partners<\/strong><\/h4>\n\n\n\n
Website: https:\/\/realizeedge.com\/en\/<\/a><\/p>\n\n\n\n